Add to My Stocks
$6.69 $0.05 (0.74%) JNCE stock closing price Sep 19, 2018 (Closing)

The cash flow statement is one of the reports a publicly traded company like JOUNCE THERAPTC needs to disclose. The profit-loss statement shows JOUNCE THERAPTC profits, the balance sheet shows JOUNCE THERAPTC debt, and the cash flow statement reflects the liquidity and solvency of a firm. This statement reflects the company's ability to generate cash flows. Items like capital purchases, bank loan payments etc. which have a direct impact on the cash position of a company come out through the statemement of cash flows and help an investor who undertakes the JOUNCE THERAPTC stock analysis. JOUNCE THERAPTC generated $-25.68M cash from operating activities in till this quarter of 2018 Q2. JOUNCE THERAPTC has a positive cash and cash equivalents change of $26.55M.

View and download details of JOUNCE THERAPTC cash flows for latest & last 40 quarters
show more
View Previous Quarters
View Next Quarters
Fiscal year is Jan - Dec2018 Q22018 Q12017 Q42017 Q32017 Q22017 Q12016 Q42016 Q32016 Q22016 Q1
Net Income Cash Flow
Depreciation Depletion Amortization Cash-Flow1.77M1.11M5.59M4.36M3.14M1.24M2.27M1.48M--
Net Increase (Decrease) in Assets Liabilities-14.37M-11.47M-84.73M-61.73M-39.65M-20.4M186.13M205.52M-2.04M-1.45M
Cash From (used in) Discontinued Operations----------
Other Adjustments Net4.63M2.26M4.85M-2.37M-2.5M1.33M4.98M3.72M1.09M-
Net Cash from (used by) Operating Activities
Increase (Decrease) in Prop Plant And Equipment-0.96M-0.23M-15.1M-13.69M-11.96M-7.07M-2.22M-1.25M-0.63M-0.25M
Acquisition Disposition of Subsidiaires----------
Increase (Decrease) in Investments52.02M119.81M-22.91M-43.01M-54.55M-65.77M-213.28M-182.27M--
Other Cash Inflow (Outflow) from Investment Activities----------
Net Cash from (used by) Investment Activities
Issuance (Purchase) of Equity Shares1.17M-107.47M107.3M107.15M107.43M36.12M36.12M--
Issuance (Repayment) of Debt Securities----------
Increase (Decrease) in Bank & Other Borrowings----------
Payment of Dividends & Other Cash Distributions----------
Other Cash from (used by) Financing Activities-------0.62M---1.64M
Net Cash from (used by) Financing Activities
Effect of Exchange Rate Changes on Cash----------
Net Change in Cash & Cash Equivalents
Cash & Equivalents at Beginning of Year24.83M44.84M45.16M2.33M------
Cash & Equivalents at Year End51.38M124.07M23.55M28.63M43.48M61.99M44.84M89.31M21.29M31.82M
All figures in USD. M: Millions of USD, B: Billions of USD.
View Previous Quarters
View Next Quarters

The statement of cash flows comprises of cash flow from financing, cash flow from operations and cash flow from investing activities. All the three can have an impact on the stock price. The JOUNCE THERAPTC stock price history and JOUNCE THERAPTC stock comparison chart inevitably reflect its cash flow situation.

  • JOUNCE THERAPTC had a Net Change in Cash and Cash Equivalents of $26.55M in the latest quarter 2018 Q2. If a firm is able to grow its cash, it is considered to be a positive signal and could lead to a jump in the JOUNCE THERAPTC stock price, albeit too much cash on hand can imply the company has no or limited avenues for growth in which to invest this cash.
  • Cash Flow from operating activities: Operating activities include the core business activities. This line item refers to the cash generated from the same and stood at a negative value of $-25.68M for JNCE.
  • Cash Flow from investment activities: JOUNCE THERAPTC generated $51.06M cash due to investment activities. It includes the use of cash outside of normal day to day activities like buying fixed assets, plant and machinery etc.
  • Cash Flow from financing activities: Financing activities include the cash that comes into a company in the form of loans or interest earned or shareholders money, as well as the cash that goes out. JOUNCE THERAPTC earned $1.17M from financing activities,in the form of repayment of loans or interest paid, dividend pay-out to shareholders etc.

Key Financial Ratios For JOUNCE THERAPTC Cash Flow

Quarterly Cash Flow Statements For JOUNCE THERAPTC Peers

Ardelyx cash flow, Galectin Therapeutics cash flow, Galmed Pharma cash flow, IMV INC cash flow